Within the BRCA2 mutation-positive group, homozygous Ins16 carriers had a significantly older age of diagnosis of breast cancer compared to the mean age of diagnosis of either of the homozygous Ins16minus (p = 0.042) or heterozygous (p = 0.046) carriers. Here, BRCA2 is linked to breast cancer.